On the other hand, a post hoc analysis of the FOURIER trial treatment with PCSK9 inhibitor evolocumab demonstrated a 46% relative risk reduction in venous thromboembolism (hazard ratio 0.54, 95% CI 0.33–0.88, p = 0.014) [78]. Here, PCSK9 is linked to venous thromboembolism.